Avenue Therapeutics (49Y) AI Stock Analysis

1 Followers

Avenue Therapeutics

(Dusseldorf:49Y)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Debt-free balance sheetThe absence of debt reduces financial leverage and interest-burden risk, leaving fewer mandatory claims on future cash flows. Although the company remains financially constrained, a debt-free structure can provide more flexibility than a highly leveraged balance sheet if funding or partnership opportunities emerge.

Negative Factors

No current recurring revenueThe return to zero trailing-twelve-month revenue indicates that commercial traction is not currently dependable. Without recurring product or partnership revenue, the company has limited internal funding capacity and remains exposed to delays in approvals, licensing, or future commercialization.

Avenue Therapeutics (49Y) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 922.59K
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -0.3
Beta (1Y): -0.19
Revenue Growth: ―
EPS Growth: ―
Country: Germany
Employees: 1
Sector: General
Sector Strength: 55
Industry: Biotechnology

Avenue Therapeutics Business Overview & Revenue Model

Company Description

Avenue Therapeutics, Inc. functions as a specialized pharmaceutical enterprise, primarily dedicated to innovating and bringing to market medical therapies tailored for critical and intensive care environments within hospitals. Their leading product c...

Avenue Therapeutics Risk Analysis

Avenue Therapeutics disclosed 65 risk factors in its most recent earnings report. Avenue Therapeutics reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Avenue Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

DE:49Y against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
SKYE	45Neutral	$4.07M	-0.11	-329.08%	―	―	-19.07%
ADXN	44Neutral	$3.29M	-0.72	-172.76%	―	-45.76%	-3.77%
CTXR	43Neutral	$13.19M	-0.25	-67.15%	―	―	57.48%
ENSC	40Underperform	$7.01M	-0.14	-1532.33%	―	-39.29%	27.41%
CALC	39Underperform	$8.55M	-0.28	-3029.57%	―	―	45.29%

* General Sector Average

Performance Comparison

DE:49Y and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:49Y	Avenue Therapeutics	0.40	0.00	0.00%
ENSC	Ensysce Biosciences, Inc.	0.39	-1.67	-81.21%
CTXR	Citius Pharma	0.53	-0.45	-45.66%
SKYE	Skye Bioscience, Inc.	1.08	-9.32	-89.62%
CALC	Calcimedica, Inc.	1.22	-13.78	-91.87%
ADXN	Addex Therapeutics Ltd (ADR)	5.29	-3.18	-37.54%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Avenue Therapeutics AI Stock Analysis